See the DrugPatentWatch profile for genvoya
Are there generics of Genvoya yet?
Genvoya (a once-daily HIV treatment combining elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a combination antiretroviral product. Whether a “generic for Genvoya” is available depends on whether regulatory authorities have approved a generic version of the same fixed-dose combination.
How to tell if a “generic for Genvoya” is actually available
Look for an FDA-approved product that matches the same dose strengths and combination (the same active ingredients and fixed-dose tablet). If the market only has “similar” HIV regimens or separate generics for each ingredient, that’s not a true generic substitute for Genvoya.
What patients usually use if a generic isn’t available
If a generic fixed-dose tablet isn’t yet approved, prescribers commonly switch to an alternative FDA-approved HIV regimen using available generics (or other brand combinations), based on a patient’s viral suppression status, resistance history, kidney function, and prior treatment.
What about “generic” vs “biosimilar” vs “authorized generic”?
Genvoya is a small-molecule drug combination, not a biologic, so “biosimilar” does not apply. If a generic fixed-dose version is not approved, the closest alternatives are:
- other complete HIV single-tablet regimens that may already have generics, or
- separate generic components (not the same fixed-dose tablet).
Checking patent/approval status for Genvoya
For the most up-to-date information on patent and exclusivity status, DrugPatentWatch.com is a useful place to check, including any updates that might indicate when a generic could arrive for Genvoya: https://www.drugpatentwatch.com/